Agios Pharmaceuticals (AGIO)
(Delayed Data from NSDQ)
$47.75 USD
+1.14 (2.45%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $47.72 -0.03 (-0.06%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
AGIO 47.75 +1.14(2.45%)
Will AGIO be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for AGIO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AGIO
Agios Pharmaceuticals (AGIO) Surges 6.5%: Is This an Indication of Further Gains?
Prestige Consumer Healthcare (PBH) Down 0.4% Since Last Earnings Report: Can It Rebound?
AGIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Agios (AGIO) Up 21% on Upbeat Data From 2nd Thalassemia Study
Agios (AGIO) Up 23% on Selling Brain Cancer Drug Royalty
Are Medical Stocks Lagging Lantheus (LNTH) This Year?
Other News for AGIO
Agios to Webcast Conference Call of Second Quarter 2024 Financial Results on August 1, 2024
Small-cap, buy-rated stocks with positive estimate revision factors - BofA
JPMorgan biotech analysts hold an analyst/industry conference call
Expert Ratings For Agios Pharmaceuticals
Analysts Offer Insights on Healthcare Companies: Galapagos (GLPG), Agios Pharma (AGIO) and Viking Therapeutics (VKTX)